These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21862312)

  • 1. Recent developments in engineering and delivery of protein and antibody therapeutics.
    Fernández LÁ; Muyldermans S
    Curr Opin Biotechnol; 2011 Dec; 22(6):839-42. PubMed ID: 21862312
    [No Abstract]   [Full Text] [Related]  

  • 2. Advancing protein therapeutics: current challenges in protein therapeutics -- CHI's Second Annual Conference.
    He M
    IDrugs; 2006 Mar; 9(3):177-8. PubMed ID: 16523380
    [No Abstract]   [Full Text] [Related]  

  • 3. Introduction to current and future protein therapeutics: a protein engineering perspective.
    Carter PJ
    Exp Cell Res; 2011 May; 317(9):1261-9. PubMed ID: 21371474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New technologies for the engineering of novel protein therapeutics and the personalization of medicine.
    Dorner AJ; Projan S
    Curr Opin Pharmacol; 2008 Oct; 8(5):598-9. PubMed ID: 18773971
    [No Abstract]   [Full Text] [Related]  

  • 5. Engineering antibodies for clinical applications.
    Jain M; Kamal N; Batra SK
    Trends Biotechnol; 2007 Jul; 25(7):307-16. PubMed ID: 17512622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing therapeutic proteins by engineering ligand-receptor interactions.
    Jones DS; Silverman AP; Cochran JR
    Trends Biotechnol; 2008 Sep; 26(9):498-505. PubMed ID: 18675482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in protein therapeutics.
    Woodnutt G; Violand B; North M
    Curr Opin Drug Discov Devel; 2008 Nov; 11(6):754-61. PubMed ID: 18946840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tailor-made antibody therapeutics.
    Chowdhury PS; Wu H
    Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein engineering: The fate of fingers.
    Pearson H
    Nature; 2008 Sep; 455(7210):160-4. PubMed ID: 18784697
    [No Abstract]   [Full Text] [Related]  

  • 11. Glycosylation of recombinant antibody therapeutics.
    Jefferis R
    Biotechnol Prog; 2005; 21(1):11-6. PubMed ID: 15903235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial: biopharmaceutical technologies.
    Jungbauer A
    Biotechnol J; 2007 Jun; 2(6):647. PubMed ID: 17570696
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibody Engineering--IBC's 17th annual international conference. Antibody engineering and immunotherapeutics for the 21st century.
    Bradbury A
    IDrugs; 2007 Mar; 10(3):169-72. PubMed ID: 17351868
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-Antibody Protein Therapeutics Development & Production--IBC Conference. Successful strategies for bringing protein therapeutics to market.
    Thorne B
    IDrugs; 2009 May; 12(5):271-4. PubMed ID: 19431086
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunogenicity of protein therapeutics.
    De Groot AS; Scott DW
    Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein engineering for therapeutics, Part A. Preface.
    Wittrup KD; Verdine GL
    Methods Enzymol; 2012; 502():xiii-xiv. PubMed ID: 22208991
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibody engineering--IBC's 15th Annual International Conference. 30 November-3 December 2004, San Diego, CA, USA.
    Haurum JS
    IDrugs; 2005 Feb; 8(2):91-3. PubMed ID: 15696403
    [No Abstract]   [Full Text] [Related]  

  • 18. Discovering and improving novel peptide therapeutics.
    McGregor DP
    Curr Opin Pharmacol; 2008 Oct; 8(5):616-9. PubMed ID: 18602024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.
    Presta LG
    Adv Drug Deliv Rev; 2006 Aug; 58(5-6):640-56. PubMed ID: 16904789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phage display for engineering and analyzing protein interaction interfaces.
    Sidhu SS; Koide S
    Curr Opin Struct Biol; 2007 Aug; 17(4):481-7. PubMed ID: 17870470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.